Loading…
Employees: 48
Size G2GBIO (456160.KS) is a South Korea Health Care company (Biotechnology) with a market value of $370M, the 417th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩30,200 on 6 Nov 2026.
Performance Over six months the shares fell 64.7%, against -23.2% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 19 in its peer set.
Growth Revenue fell 45.0% over the last twelve months (peer median +2.3%); the operating margin is -2,884.2% (peer median -288.3%).
Valuation It trades at 775.0× enterprise value to sales against a peer median of 7.1× (3rd most expensive of 16).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | ₩423M | ₩769M | ₩740M | ₩241M |
| Revenue growth | — | -45% | +4% | +208% | — |
| Gross profit | n/a | -₩1.49B | -₩1.49B | -₩1.35B | -₩1.38B |
| EBITDA | n/a | -₩10.6B | -₩8.93B | -₩11.4B | -₩9.84B |
| Net income | n/a | -₩12.1B | -₩83.3B | -₩10.5B | ₩15.1B |
| Free cash flow | n/a | -₩14.2B | -₩8.55B | -₩11.8B | -₩14.4B |
| Capital expenditure | n/a | ₩324M | ₩844M | ₩970M | ₩5.68B |
| Total debt | ₩41.9B | ₩7.13B | ₩115B | ₩56.3B | ₩52.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 456160.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -32.4% | -9.5% | 4th lowest of 20 |
| 6-month return | -64.7% | -23.2% | 2nd lowest of 19 |
| Distance from 52-week high | -75.7% | -51.2% | 4th lowest of 20 |
| Revenue growth (TTM) | -45.0% | +2.3% | 5th lowest of 16 |
| Operating margin | -2,884.2% | -288.3% | 4th lowest of 16 |
| EV / Sales | 775.0× | 7.1× | 3rd most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | 7.1× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |